Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | CCR5 | P51681 | 6/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2407533 | 0.92 | KCNH2 (0.49) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL2575803 | 0.86 | MEN1 (0.51) | MEN1KMT2ACCR5SIGMAR1KCNH2 | |
| SCHEMBL4283829 | 0.86 | CCR5 (0.62) | KMT2ACCR5SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL11394433 | 0.84 | SIGMAR1 (0.64) | NPC1RAB9AMEN1KMT2APOLB | |
| SCHEMBL13956186 | 0.84 | MEN1 (0.49) | NPC1RAB9AMEN1KMT2ACCR5 | |
| SCHEMBL16299033 | 0.82 | MEN1 (0.77) | NPC1RAB9AMEN1KMT2ACCR5 | |
| Hydrochloric Acid SCHEMBL11530039 | 0.81 | SIGMAR1 (0.56) | NPC1RAB9AMEN1KMT2ASIGMAR1 | |
| SCHEMBL17896798 | 0.81 | NPC1 (0.56) | NPC1MEN1KMT2APOLBCCR5 | |
| SCHEMBL2405156 | 0.79 | CCR5 (0.60) | NPC1RAB9ACCR5SIGMAR1KCNH2 | |
| SCHEMBL23680337 | 0.78 | MEN1 (0.58) | NPC1RAB9AMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669271-B2 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-03-11 | — | — | US | disclosed |
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120322784-A1 | Compounds, pharmaceutical compositions and uses thereof | GPR119, GPR3, MRGPRX2 | NPC1 606/4885RAB9A 1196/4885MEN1 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.